Published on September 6, 2012 at 1:37 AM
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC)
announced today that the company has completed enrollment for its Phase
II randomized, double-blinded, placebo-controlled, multi-center trial of
its dendritic cell-based cancer vaccine ICT-107 for treatment of
glioblastoma. A total of 278 patients at 25 participating sites have
been enrolled in this trial, which was initiated in January 2011.
"We believe that ICT-107 represents the next generation of cancer
immunotherapy by targeting both tumor cells and cancer stem cells with a
dendritic cell-based vaccine," said John. S. Yu, MD, ImmunoCellular's
Interim Chief Executive Officer. "We deeply appreciate the oncology
community's enthusiasm for the ICT-107 clinical program and their shared
interest in exploring the therapeutic potential of this potentially
breakthrough technology, as reflected in the pace of enrollment in the
trial. I congratulate the ImmunoCellular clinical team for this
successful milestone in efficiently and rapidly completing enrollment in
this complex clinical trial."
"This potential vaccine tested in patients with Stage IV glioblastoma is
designed to leverage the patient's own immune system after surgery and
chemo-radiation treatments to hunt and destroy remaining brain tumor
cancer cells," says Dr. John Boockvar, director of the Brain Tumor
Research Group, associate professor of neurological surgery at Weill
Cornell Medical College and a neurosurgeon at NewYork-Presbyterian
Hospital/Weill Cornell Medical Center - one of the clinical trial
testing sites for the experimental vaccine. "Previous Phase I study
results show the vaccine may improve patient survival by enabling them
to remain disease-free longer when the vaccine is combined with standard
treatments. I look forward to seeing the Phase II results."
Source: ImmunoCellular Therapeutics, Ltd.